Literature DB >> 28384843

A design for phase I trials in completely or partially ordered groups.

Mark R Conaway1.   

Abstract

We propose a design for dose finding for cytotoxic agents in completely or partially ordered groups of patients. By completely ordered groups, we mean that prior to the study, there is clinical information that would indicate that for a given dose, the groups can be ordered with respect to the probability of toxicity at that dose. With partially ordered groups, at a given dose, only some of the groups can be ordered with respect to the probability of toxicity at that dose. The method we propose includes elements of the parametric model used in the continual reassessment method combined with the Hwang-Peddada order-restricted estimation procedure. We evaluate the operating characteristics of these designs in a family of dose-toxicity curves representing complete and partial orders.
Copyright © 2017 John Wiley & Sons, Ltd. Copyright © 2017 John Wiley & Sons, Ltd.

Entities:  

Keywords:  cytotoxic agent; dose finding; heterogeneous groups

Mesh:

Substances:

Year:  2017        PMID: 28384843      PMCID: PMC5571448          DOI: 10.1002/sim.7295

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  23 in total

1.  Designs for single- or multiple-agent phase I trials.

Authors:  Mark R Conaway; Stephanie Dunbar; Shyamal D Peddada
Journal:  Biometrics       Date:  2004-09       Impact factor: 2.571

2.  Identifying a maximum tolerated contour in two-dimensional dose finding.

Authors:  Nolan A Wages
Journal:  Stat Med       Date:  2016-02-22       Impact factor: 2.373

3.  Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer.

Authors:  Federico Innocenti; Richard L Schilsky; Jacqueline Ramírez; Linda Janisch; Samir Undevia; Larry K House; Soma Das; Kehua Wu; Michelle Turcich; Robert Marsh; Theodore Karrison; Michael L Maitland; Ravi Salgia; Mark J Ratain
Journal:  J Clin Oncol       Date:  2014-06-23       Impact factor: 44.544

4.  Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1*28 and/or UGT1A1*6 polymorphisms.

Authors:  Taroh Satoh; Takashi Ura; Yasuhide Yamada; Kentaro Yamazaki; Toshimasa Tsujinaka; Masaki Munakata; Tomohiro Nishina; Shu Okamura; Taito Esaki; Yasutsuna Sasaki; Wasaburo Koizumi; Yoshihiro Kakeji; Naoki Ishizuka; Ichinosuke Hyodo; Yuh Sakata
Journal:  Cancer Sci       Date:  2011-08-12       Impact factor: 6.716

5.  Bivariate isotonic design for dose-finding with ordered groups.

Authors:  Anastasia Ivanova; Kai Wang
Journal:  Stat Med       Date:  2006-06-30       Impact factor: 2.373

6.  Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study.

Authors:  Ticiana B Leal; Scot C Remick; Chris H Takimoto; Ramesh K Ramanathan; Angela Davies; Merrill J Egorin; Anne Hamilton; Patricia A LoRusso; Stephen Shibata; Heinz-Josef Lenz; James Mier; John Sarantopoulos; Sridhar Mani; John J Wright; S Percy Ivy; Rachel Neuwirth; Lisa von Moltke; Karthik Venkatakrishnan; Daniel Mulkerin
Journal:  Cancer Chemother Pharmacol       Date:  2011-04-09       Impact factor: 3.333

7.  Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group.

Authors:  Ramesh K Ramanathan; Merrill J Egorin; Chris H M Takimoto; Scot C Remick; James H Doroshow; Patricia A LoRusso; Daniel L Mulkerin; Jean L Grem; Anne Hamilton; Anthony J Murgo; Douglas M Potter; Chandra P Belani; Michael J Hayes; Bin Peng; S Percy Ivy
Journal:  J Clin Oncol       Date:  2008-02-01       Impact factor: 44.544

8.  Continual reassessment method for ordered groups.

Authors:  John O'Quigley; Xavier Paoletti
Journal:  Biometrics       Date:  2003-06       Impact factor: 2.571

9.  Bridging Solutions in Dose Finding Problems.

Authors:  John O'Quigley; Alexia Iasonos
Journal:  Stat Biopharm Res       Date:  2014-05-01       Impact factor: 1.452

10.  A product of independent beta probabilities dose escalation design for dual-agent phase I trials.

Authors:  Adrian P Mander; Michael J Sweeting
Journal:  Stat Med       Date:  2015-01-29       Impact factor: 2.373

View more
  4 in total

1.  The Impact of Early-Phase Trial Design in the Drug Development Process.

Authors:  Mark R Conaway; Gina R Petroni
Journal:  Clin Cancer Res       Date:  2018-10-16       Impact factor: 12.531

2.  Shift models for dose-finding in partially ordered groups.

Authors:  Bethany Jablonski Horton; Nolan A Wages; Mark R Conaway
Journal:  Clin Trials       Date:  2018-10-11       Impact factor: 2.486

3.  Revisiting isotonic phase I design in the era of model-assisted dose-finding.

Authors:  Nolan A Wages; Mark R Conaway
Journal:  Clin Trials       Date:  2018-08-13       Impact factor: 2.486

4.  Bayesian Design for Identifying Cohort-Specific Optimal Dose Combinations Based on Multiple Endpoints: Application to a Phase I Trial in Non-Small Cell Lung Cancer.

Authors:  Bethany Jablonski Horton; Nolan A Wages; Ryan D Gentzler
Journal:  Int J Environ Res Public Health       Date:  2021-10-30       Impact factor: 3.390

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.